Covalon Technologies Ltd
XTSX:COV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Covalon Technologies Ltd
XTSX:COV
|
CA |
|
U
|
United States Antimony Corp
AMEX:UAMY
|
US |
|
American States Water Co
NYSE:AWR
|
US |
|
D
|
Digital Network SA
WSE:DIG
|
PL |
|
Cewe Stiftung & Co KGaA
XETRA:CWC
|
DE |
|
Technical Publications Service SpA
MIL:TPS
|
IT |
|
Kyndryl Holdings Inc
NYSE:KD
|
US |
|
AxoGen Inc
NASDAQ:AXGN
|
US |
|
E
|
EvoAir Holdings Inc
OTC:EVOH
|
MY |
Covalon Technologies Ltd
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of patent-protected medical products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-09-03. The firm uses science and technology to help solve medical challenges associated with prevention, detection and management of areas such as infection, tissue repair and medical devices. Its products include Advanced Wound Care, Vascular Access, Perioperative Care and Urology. Advanced Wound Care is designed for the treatment of a range of wounds and offers CovaWound and ColActive brands. Vascular Access portfolio includes CovaView IV, a transparent film dressing that provides an effective barrier against external contaminants, including fluid, bacteria, and yeast. Perioperative care refers to the three Phases of surgery, including preoperative, intraoperative, and postoperative care and its brands include MediClear and SurgiClear.
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of patent-protected medical products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-09-03. The firm uses science and technology to help solve medical challenges associated with prevention, detection and management of areas such as infection, tissue repair and medical devices. Its products include Advanced Wound Care, Vascular Access, Perioperative Care and Urology. Advanced Wound Care is designed for the treatment of a range of wounds and offers CovaWound and ColActive brands. Vascular Access portfolio includes CovaView IV, a transparent film dressing that provides an effective barrier against external contaminants, including fluid, bacteria, and yeast. Perioperative care refers to the three Phases of surgery, including preoperative, intraoperative, and postoperative care and its brands include MediClear and SurgiClear.
Q1 Revenue: Revenue declined compared to the same quarter last year, but management emphasized this is not a trend and said Q2 sales and orders are already exceeding Q1 levels, with confidence in strong results for the rest of fiscal 2026.
Gross Margin: Gross margin in Q1 was just over 58%, down a few points year-on-year but still well above major competitors and the company's recent annual margin.
Operational Progress: Covalon has secured new high-profile hospital customers, including Mayo Clinic and Memorial Sloan Kettering, for its infection prevention products, and is expanding its reach into adult acute care hospitals.
Product Momentum: The company’s VALGuard and CovaClear IV solutions are gaining traction and clinical endorsements, with momentum supported by new clinical evidence and educational partnerships.
CapEx & Efficiency: Investments have been made in automation equipment and IT improvements, aimed at boosting manufacturing capacity and efficiency.
Cash & Buybacks: Despite returning over $4 million to shareholders, Covalon increased its cash balance in Q1 and is considering options like share buybacks, dividends, or M&A.
Customer Retention: The company reported a 100% retention rate among its top 50 customers from a year ago and continues to add dozens of new accounts.
Strategic Interest: Management says Covalon is attracting increased attention from major med tech companies and private equity for potential partnerships or acquisitions.
